Paying the price in an era of HIV treatment as prevention: a retrospective study of the cost burden of HIV treatment for people living with HIV in Victoria, Australia
Anna L. Wilkinson A B F , James McMahon A C , Yik-Siang Cheah A , Catriona S. Bradshaw D E , Carol El-Hayek A and Mark Stoové A B
+ Author Affiliations
- Author Affiliations
A Centre for Population Health, Burnet Institute, 85 Commercial Road, Melbourne, Vic. 3004, Australia.
B School of Public Health and Preventive Medicine, Monash University, Alfred Hospital, Commercial Road, Melbourne, Vic. 3004, Australia.
C Department of Infectious Diseases, Alfred Health and Monash University, Alfred Hospital, Commercial Road, Melbourne, Vic. 3004, Australia.
D Alfred Health, Melbourne Sexual Health Centre, 580 Swanston Street, Carlton, Vic. 3053, Australia.
E Monash University, Central and Eastern Clinical School, Faculty of Medicine, Nursing and Health Sciences, Monash University, Alfred Hospital, Commercial Road, Melbourne, Vic. 3004, Australia.
F Corresponding author. Email: awilkinson@burnet.edu.au
Sexual Health 12(1) 34-38 https://doi.org/10.1071/SH14144
Submitted: 29 July 2014 Accepted: 4 November 2014 Published: 22 December 2014
Abstract
Background: An estimated 25 700 people live with diagnosed HIV (PLWH) in Australia and ~1200 newly diagnosed cases were notified in 2012. New HIV prevention strategies focus on individual uptake of treatment; however, a potential barrier is the financial burden of antiretroviral treatment (ART). We describe HIV ART dispensed and the estimated associated costs for PLWH in Victoria. Methods: A retrospective cross-sectional study of pharmacy data on ART dispensed between January 2012 and November 2013 from a hospital network, including Victoria’s largest sexual health clinic was conducted. Estimated annual patient costs of ART were calculated by the number of items dispensed per year, concession status, dispensing site and applicable co-payment. Results: A total of 60 225 dispensing records from 3903 individuals were included; this represented 83.8% of pharmaceutical benefits scheme-recorded ART dispensed in Victoria over this period. The estimated annual co-payment costs for patients without a concession card and who were collecting two medications was $433.20. One-fifth of patients (21.3%) collected four or more items, equating to an estimated annual cost of at least $866.40 without a concession card and $141.60 with a concession card. Of those dispensed four or more items, 40.4% were concession card holders. Conclusions: There may be meaningful patient costs associated with accessing ART for some PLWH. New HIV treatment-based prevention strategies need to consider financial vulnerabilities and appropriately targeted initiatives to alleviate patient costs associated with ART, ensuring they do not act as a barrier to commencement of and adherence to HIV treatment.
Additional keywords: antiretroviral treatment, medication costs.
References
[1] The Kirby Institute. HIV, viral hepatitis and sexually transmissable infections in Australia. Annual Surveillance Report 2013. Sydney: The Kirby Institute; 2013.[2] The Antiretroviral Therapy Cohort Collaboration Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008; 372 293–9.
| Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies.Crossref | GoogleScholarGoogle Scholar | 18657708PubMed |
[3] de Wit J, Mao L, Holt M, Treloar C, editors. HIV/AIDS, hepatitis and sexually transmissible infections in Australia: annual report of trends in behaviour 2013 (Monograph 6/2013). Sydney: The Kirby Institute; 2013.
[4] Wilson DP. HIV treatment as prevention: natural experiments highlight limits of antiretroviral treatment as HIV prevention. PLoS Med 2012; 9 e1001231
| HIV treatment as prevention: natural experiments highlight limits of antiretroviral treatment as HIV prevention.Crossref | GoogleScholarGoogle Scholar | 22807656PubMed |
[5] Rodger A, Bruun T, Cambiano V, Vernazza P, Estrada V, Van Lunzen J, et al., editors. Abstract 153LB: HIV transmission risk through condomless sex if HIV+ partner on suppressive ART: PARTNER Study. Conference in Retroviruses and Opportunistic Infections (CROI); 3–6 March 2014; Boston, Massachusetts, USA.
[6] Department of Health. About the PBS Canberra, Australia: Australian Government; 2013. Available online at: http://www.pbs.gov.au/info/about-the-pbs#What_is_the_PBS [verified 17 October 2013].
[7] Department of Health Northern Territory. Clinic 34 - Free and Confidential Sexual Health Service Northern Territory, Australia: Northern Territory Government; 2013. Available online at: http://www.health.nt.gov.au/Clinic_34/ [verified 12 December 2013].
[8] Heymer KJ, Wentzlaff-Eggebert M, Mortimer E, Wilson DP. An economic case for providing free access to antiretroviral therapy for HIV-positive people in South Australia. Sex Health 2012; 9 220–6.
| An economic case for providing free access to antiretroviral therapy for HIV-positive people in South Australia.Crossref | GoogleScholarGoogle Scholar | 22697138PubMed |
[9] Melbourne Sexual Health Centre. Melbourne Sexual Health Cente HIV/AIDS Clinic. Melbourne: Melbourne Sexual Health Centre; 2013. Available online at: http://www.mshc.org.au/general/Home/tabid/145/Default.aspx [verified 18 December 2013].
[10] Australasian Society for HIV Medicine. ASHM Trained HIV s100 Prescribers NSW, Australia: Australasian Society for HIV Medicine; 2013 [updated 20 November 2013]. Available online at: http://www.ashm.org.au/images/prescriber/ashmprescribers.pdf [verified 23 December 2013].
[11] The Kirby Insitute and National Association of People with HIV Australia. The Australian HIV Observational Database Temporary Residents Access Study (ATRAS): one year follow up. Sydney: The Kirby Institute; 2013.
[12] Hynd A, Roughead EE, Preen DB, Glover J, Bulsara M, Semmens J. The impact of co-payment increases on dispensings of government-subsidised medicines in Australia. Pharmacoepidemiol Drug Saf 2008; 17 1091–9.
| The impact of co-payment increases on dispensings of government-subsidised medicines in Australia.Crossref | GoogleScholarGoogle Scholar | 18942671PubMed |
[13] Chen SY, Shah SN, Lee YC, Boulanger L, Mardekian J, Kuznik A. Moving branded statins to lowest copay tier improves patient adherence. J Manag Care Pharm 2014; 20 34–42.
| 24372458PubMed |
[14] Tuller DM, Bangsberg DR, Senkungu J, Ware NC, Emenyonu N, Weiser SD. Transportation costs impede sustained adherence and access to HAART in a clinic population in southwestern Uganda: a qualitative study. AIDS Behav 2010; 14 778–84.
| Transportation costs impede sustained adherence and access to HAART in a clinic population in southwestern Uganda: a qualitative study.Crossref | GoogleScholarGoogle Scholar | 19283464PubMed |
[15] Harrigan PR, Hogg RS, Dong WW, Yip B, Wynhoven B, Woodward J, et al Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis 2005; 191 339–47.
| Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD2MXhtlKrtbo%3D&md5=0e815dfc41c970f95f43357252b700c9CAS | 15633092PubMed |
[16] Department of Human Services. Pharmaceutical benefits schedule item reports. Canberra, Australia: Australian Government. Available online at: https://www.medicareaustralia.gov.au/statistics/pbs_item.shtml [cited 02 January 2014].
[17] Pour SM, Woolley I, Canavan P, Chuah J, Russell DB, Law M, et al Triple class experience after initiation of combination antiretroviral treatment in Australia: survival and projections. Sex Health 2011; 8 295–303.
| Triple class experience after initiation of combination antiretroviral treatment in Australia: survival and projections.Crossref | GoogleScholarGoogle Scholar | 21851768PubMed |
[18] Yusuf F, Leeder SR. Can’t escape it: the out-of-pocket cost of health care in Australia. Med J Aust 2013; 199 475–8.
| Can’t escape it: the out-of-pocket cost of health care in Australia.Crossref | GoogleScholarGoogle Scholar | 24099208PubMed |
[19] Schoen C, Osborn R, Squires D, Doty MM, Pierson R, Applebaum S. How health insurance design affects access to care and costs, by income, in eleven countries. Health Aff 2010; 29 2323–34.
| How health insurance design affects access to care and costs, by income, in eleven countries.Crossref | GoogleScholarGoogle Scholar |
[20] Essue B, Kelly P, Roberts M, Leeder S, Jan S. We can’t afford my chronic illness! The out-of-pocket burden associated with managing chronic obstructive pulmonary disease in western Sydney, Australia. J Health Serv Res Policy 2011; 16 226–31.
| We can’t afford my chronic illness! The out-of-pocket burden associated with managing chronic obstructive pulmonary disease in western Sydney, Australia.Crossref | GoogleScholarGoogle Scholar | 21954233PubMed |
[21] McAllister J, Beardsworth G, Lavie E, MacRae K, Carr A. Financial stress is associated with reduced treatment adherence in HIV-infected adults in a resource-rich setting. HIV Med 2013; 14 120–4.
| Financial stress is associated with reduced treatment adherence in HIV-infected adults in a resource-rich setting.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DC%2BC38jovVWisA%3D%3D&md5=64bfa663498f3e8fa93b9ae08bd5b4f3CAS | 22780330PubMed |
[22] Parienti JJ, Massari V, Descamps D, Vabret A, Bouvet E, Larouze B, et al Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy. Clin Infect Dis 2004; 38 1311–6.
| Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD2cXksFersL8%3D&md5=ee1d14b317a9971828b839599ca422bfCAS | 15127346PubMed |
[23] Oyugi JH, Byakika-Tusiime J, Ragland K, Laeyendecker O, Mugerwa R, Kityo C, et al Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. AIDS 2007; 21 965–71.
| Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD2sXksFemsbo%3D&md5=27cc596dcf042fd0e54af947e34f7f5aCAS | 17457090PubMed |
[24] Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009; 373 48–57.
| Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model.Crossref | GoogleScholarGoogle Scholar | 19038438PubMed |
[25] Montaner JSG, Lima VD, Barrios R, Yip B, Wood E, Kerr T, et al Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet 2010; 376 532–9.
| Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study.Crossref | GoogleScholarGoogle Scholar |
[26] Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365 493–505.
| Prevention of HIV-1 infection with early antiretroviral therapy.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC3MXhtVars7jF&md5=f28f0bc4d943ad7366817444e30a0eaeCAS | 21767103PubMed |
[27] Australasian Society for HIV Medicine. 2013 Antiretroviral guidelines with Australian commentary. Sydney, Australia: Australasian Society for HIV Medicine; 2014. Available online at: http://arv.ashm.org.au/clinical-guidance [cited 15 July 2014].
[28] Department of Health. Health-2014–15 budget at a glance. Canberra: Australian Government; 2014. Available online at: https://www.mja.com.au/journal/2014/200/11/can-we-sustain-health-spending [cited 15 June 2014].
[29] Richardson J. Can we sustain health spending? Med J Aust 2014; 200 629–31.
| Can we sustain health spending?Crossref | GoogleScholarGoogle Scholar | 24938335PubMed |
[30] Furuya-Kanamori L, Kelly MD, McKenzie SJ. Co-morbidity, ageing and predicted mortality in antiretroviral treated Australian men: a quantitative analysis. PLoS ONE 2013; 8 e78403
| Co-morbidity, ageing and predicted mortality in antiretroviral treated Australian men: a quantitative analysis.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC3sXhslWksL7O&md5=1fc5b212b59204dcb08cb31276a2c51eCAS | 24205222PubMed |
[31] Baker D. Bulk billing: missing out on fair and affordable health care. Canberra, Australia: The Australian Institute; 2011.
[32] The Auditor-General. Medicare Australia’s administration of the pharmaceutical benefits scheme. Canberra, ACT: Australia; 2010.
[33] Jan S, Essue BM, Leeder SR. Falling through the cracks: the hidden economic burden of chronic illness and disability on Australian households. Med J Aust 2012; 196 29–31.
| Falling through the cracks: the hidden economic burden of chronic illness and disability on Australian households.Crossref | GoogleScholarGoogle Scholar | 22256924PubMed |
